Diagnostic tests and treatment options in glomerular disease: 2014 update
- PMID: 24239051
- DOI: 10.1053/j.ajkd.2013.09.019
Diagnostic tests and treatment options in glomerular disease: 2014 update
Abstract
Glomerular diseases historically have been challenging disorders to comprehend and treat for patients and physicians alike. Kidney biopsy is the gold standard of diagnosis, but the link between pathophysiology and the histologic representation of kidney injury has remained elusive in many of these diseases. As a result, treatment of glomerular disease usually involves therapies that are not specific to disease pathogenesis, such as blockade of the renin-angiotensin-aldosterone system and various immunosuppression regimens. Recent research has resulted in greater insight into some glomerular diseases, leading to the hope that new diagnostic tests and treatments targeting disease-specific mechanisms are on the horizon. We review recent progress on the understanding, diagnosis, and treatment of 4 glomerular diseases: immunoglobulin A nephropathy, focal segmental glomerulosclerosis, the C3 glomerulopathies, and idiopathic membranous nephropathy.
Keywords: C3 glomerulopathies; Immunoglobulin A (IgA) nephropathy; focal segmental glomerulosclerosis; glomerular disease; membranous nephropathy.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Diagnosis and treatment of primary glomerular diseases. Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy.Minerva Urol Nefrol. 2005 Sep;57(3):211-36. Minerva Urol Nefrol. 2005. PMID: 15986018 Review.
-
New diagnostic tests and new therapies for glomerular diseases.Blood Purif. 2013;35(1-3):81-5. doi: 10.1159/000345185. Epub 2013 Jan 22. Blood Purif. 2013. PMID: 23343551 Review.
-
[Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].G Ital Nefrol. 2012 May-Jun;29(3):274-82; discussion 292. G Ital Nefrol. 2012. PMID: 22718450 Italian.
-
Mycophenolate mofetil in primary glomerulopathies.Kidney Int. 2008 Jan;73(2):154-62. doi: 10.1038/sj.ki.5002653. Epub 2007 Nov 7. Kidney Int. 2008. PMID: 17989649 Review.
-
B cell suppression in primary glomerular disease.Adv Chronic Kidney Dis. 2014 Mar;21(2):166-81. doi: 10.1053/j.ackd.2014.01.005. Adv Chronic Kidney Dis. 2014. PMID: 24602466 Review.
Cited by
-
CALINCA-A Novel Pipeline for the Identification of lncRNAs in Podocyte Disease.Cells. 2021 Mar 20;10(3):692. doi: 10.3390/cells10030692. Cells. 2021. PMID: 33804736 Free PMC article.
-
Urinary expression of long non-coding RNA TUG1 in non-diabetic patients with glomerulonephritides.Biomed Rep. 2021 Jan;14(1):17. doi: 10.3892/br.2020.1393. Epub 2020 Nov 20. Biomed Rep. 2021. PMID: 33365127 Free PMC article.
-
Experimental Models to Study Podocyte Biology: Stock-Taking the Toolbox of Glomerular Research.Front Pediatr. 2018 Jul 13;6:193. doi: 10.3389/fped.2018.00193. eCollection 2018. Front Pediatr. 2018. PMID: 30057894 Free PMC article. Review.
-
The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial.J Korean Med Sci. 2018 Feb 26;33(9):e74. doi: 10.3346/jkms.2018.33.e74. J Korean Med Sci. 2018. PMID: 29441742 Free PMC article. Clinical Trial.
-
The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.Ren Fail. 2017 Nov;39(1):512-518. doi: 10.1080/0886022X.2017.1325371. Ren Fail. 2017. PMID: 28562168 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
